The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $108.31

Today's change+0.42 +0.39%
Updated October 20 4:01 PM EDT. Delayed by at least 15 minutes.
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $108.31

Today's change+0.42 +0.39%
Updated October 20 4:01 PM EDT. Delayed by at least 15 minutes.

Taro Pharmaceutical Industries Ltd up (U.S.)$0.42

Taro Pharmaceutical Industries Ltd closed up Friday by (U.S.)$0.42 or 0.39% to (U.S.)$108.31. Shares have lost 1.96% over the last five days, but are unchanged over the last year to date. This security has underperformed the S&P 500 by 15.41% during the last year.

Key company metrics

  • Open(U.S.) $108.00
  • Previous close(U.S.) $107.89
  • High(U.S.) $108.70
  • Low(U.S.) $107.02
  • Bid / Ask-- / --
  • YTD % change+2.89%
  • Volume74,008
  • Average volume (10-day)54,620
  • Average volume (1-month)64,329
  • Average volume (3-month)89,680
  • 52-week range(U.S.) $92.28 to (U.S.) $124.52
  • Beta0.65
  • Trailing P/E11.05×
  • P/E 1 year forward11.41×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $9.81
Updated October 20 4:01 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+49.77%

Based on its net profit margin of 49.77%, Taro Pharmaceutical Industries Ltd is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.25%Sector:HealthcareIndustry:Pharmaceuticals - Diversified

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2018Q4/2017Q3/2017Q2/2017
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedJun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016
Revenue161196220229
Total other revenue--------
Total revenue161196220229
Gross profit117144167177
Total cost of revenue45525351
Total operating expense84959187
Selling / general / administrative24222021
Research & development15201815
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0000
Other operating expenses, total--------
Operating income78102129142
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax65100161160
Income after tax5583140124
Income tax, total10172036
Net income5483140124
Total adjustments to net income--------
Net income before extra. items5583140124
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items5583140124
Inc. avail. to common incl. extra. items5483140124
Diluted net income5483140124
Dilution adjustment--------
Diluted weighted average shares40414141
Diluted EPS excluding extraordinary itemsvalue per share1.352.053.423.00
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share1.352.053.423.00